{
    "clinical_study": {
        "@rank": "62187", 
        "arm_group": [
            {
                "arm_group_label": "Moxibustion", 
                "arm_group_type": "Experimental", 
                "description": "A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH."
            }, 
            {
                "arm_group_label": "Waiting", 
                "arm_group_type": "No Intervention", 
                "description": "Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week)."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized controlled study aimed to evaluate the effectiveness and safety of\n      moxibustion therapy on benign prostate hyperplasia(BPH) patients with moderate to severe\n      lower urinary tract symptoms(LUTS)."
        }, 
        "brief_title": "Effectiveness and Safety of Moxibustion Therapy for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Moxibustion", 
            "BPH", 
            "Benign Prostatic Hyperplasia", 
            "Benign Prostatic Hypertrophy", 
            "Lower Urinary Tract Symptom"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia", 
                "Hypertrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who diagnosed as BPH with moderate to severe LUTS aged 20 to 80 years old will be\n      divided into two groups, one is moxibustion plus conventional therapy group and the other is\n      conventional therapy group.\n\n      Patients who belong to moxibustion plus conventional therapy group will be treated\n      moxibustion for eight times by a Korean Medicine doctor with conventional therapy by a\n      urologist.\n\n      Patients who belong to conventional therapy group will be treated with conventional therapy\n      only, and they can receive moxibustion therapy after the clinical trial is finished.\n\n      IPSS,  post void residual volume (PVR) and peak urine flow (Qmax) will be checked to\n      evaluate the effectiveness and safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. male patients diagnosed benign prostate hyperplasia aged from 20 to 80 years\n\n          2. greater than or equal to eight score on IPSS\n\n          3. submit written consent\n\n          4. who can understand and answer IPSS.\n\n        Exclusion Criteria:\n\n          1. prostate or bladder malignancy\n\n          2. received herbal medication for lower urinary tract symptoms within 1 week\n\n          3. history of brain disease could cause urinary difficulty\n\n          4. having problems on answering IPSS due to cognitive impairment.\n\n          5. signs of acute urinary tract infection\n\n          6. Diabetic mellitus\n\n          7. Neurogenic bladder"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051036", 
            "org_study_id": "NC1307"
        }, 
        "intervention": {
            "arm_group_label": "Moxibustion", 
            "description": "In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).\nThe moxa pillars will be removed when the patient feel hotness and require to remove them.\nThe moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session.", 
            "intervention_name": "Moxibustion", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "djkim085@gmail.com", 
                "last_name": "Dong Jin Kim, BcS", 
                "phone": "82553605902"
            }, 
            "facility": {
                "address": {
                    "city": "Yangsa", 
                    "country": "Korea, Republic of", 
                    "state": "Kyungsangnamdo", 
                    "zip": "626-770"
                }, 
                "name": "National Clinical Research Center, Korean Medicine Hospital, Pusan National University"
            }, 
            "investigator": {
                "last_name": "Jung Nam Kwon, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study on Effectiveness and Safety of Moxibustion for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome", 
        "overall_contact": {
            "email": "syblkmj@hanmail.net", 
            "last_name": "Minjoo Kang, BcS", 
            "phone": "82553605907"
        }, 
        "overall_official": {
            "affiliation": "Korean Medicine Hospital, Pusan National University", 
            "last_name": "Jung Nam Kwon, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "International prostate symptom score (IPSS) at 4 weeks", 
            "safety_issue": "No", 
            "time_frame": "four weeks after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051036"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Korean Medicine Hospital of Pusan National University", 
            "investigator_full_name": "JUNGNAM KWON", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient's global impression of change (PGIC)", 
                "safety_issue": "No", 
                "time_frame": "four weeks, 12 weeks after randomization (both group), every visit (active group only)"
            }, 
            {
                "measure": "The Short Form (36) Health Survey (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "basline, four weeks, 12 weeks after randomization (both group). two weeks after ramdomization (active group)"
            }, 
            {
                "measure": "Maximum flow rate by uroflowmetry (Qmax)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks after randomization (both group)"
            }, 
            {
                "measure": "Post-voiding residual urine in bladder (PVR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks after randomization"
            }, 
            {
                "measure": "International Prostate Symptom Score (IPSS)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after randomization"
            }
        ], 
        "source": "Korean Medicine Hospital of Pusan National University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "JUNGNAM KWON", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}